Vanessa Quick, Mahdi Abusalameh, Sajeel Ahmed, Hoda Alkoky, Marwan Bukhari, Stuart Carter, Fiona L Coath, Brian Davidson, Parveen Doddamani, Shirish Dubey, Georgina Ducker, Bridget Griffiths, Nicola Gullick, Jonathan Heaney, Amelia Holloway, Ei Ei Phyu Htut, Mark Hughes, Hannah Irvine, Alison Kinder, Asim Kurshid, Joyce Lim, Dalia R Ludwig, Mariam Malik, Louise Mercer, Ben Mulhearn, Jagdish R Nair, Rikesh Patel, Joanna Robson, Pratyasha Saha, Sarah Tansley, Sarah L Mackie
OBJECTIVES: The National Health Service in England funds 12 months of weekly subcutaneous tocilizumab (qwTCZ) for patients with relapsing or refractory giant cell arteritis (GCA). During the COVID-19 pandemic, some patients were allowed longer treatment. We sought to describe what happened to patients after cessation of qwTCZ. METHODS: Multicentre service evaluation of relapse after stopping qwTCZ for GCA. The log-rank test was used to identify significant differences in time to relapse...
November 11, 2023: Rheumatology